Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 740 participants.

Also called NCT02173457

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 740 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02173457
Other papers using this trial's data
  • Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes Frontiers in endocrinology, 2022 DOI, PubMed 35547000, PMC9081976 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02173457. Randomized; double masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2017-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
Acronym
CMAS
Intervention (Drug)
Chiglitazar
Intervention (Drug)
Sitagliptin
Lead sponsor
Chipscreen Biosciences, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02173457
Content hash
fdeb3dfbc0caebacfebb74c9cb160087c5943f21b23eff6c287ac1062898746f